Jorveza
What Jorveza is used for
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of eosinophilic esophagitis (EoE) in paediatric patients 2 to 17 years of age.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Jorveza
- Active substance
- budesonide
- Disease area
- Esophageal Diseases
- Medicine group
- Antidiarrheals, intestinal antiinflammatory / antiinfective agents
- ATC code
- A07EA06
- Marketing authorisation holder
- Dr. Falk Pharma GmbH
- Authorised in the EU since
- 2018
Official information
In India
- Budesonide: 226 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jorveza used for?
Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of eosinophilic esophagitis (EoE) in paediatric patients 2 to 17 years of age.
What is the active substance in Jorveza?
Jorveza contains budesonide.
Who makes Jorveza?
The EU marketing authorisation holder is Dr. Falk Pharma GmbH.
Is Jorveza an orphan medicine?
Yes. Jorveza is designated an orphan medicine in the EU, for a rare disease (Esophageal Diseases).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU